看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。: I1 o+ L3 j6 x; f2 x8 F+ d
2 g0 a. ~! L# `; u# [, w+ ]. L2 f: W9 ~' I/ ~! H& Q
Currently available feasibility data for possible combination strategies.
6 X, V8 ?3 [. \% l1 M* }! ?————————————————————————————————
8 \! Q j, X+ h P' gCombination Feasibility according to preliminary data
. t G( H4 M0 U) t2 w' [——————————————————————————————————% } L: }8 E! Z) w
Bevacizumab + sorafenib Yes, reduced dose
( q# |3 |0 }& @: K$ ]Bevacizumab + sunitinib† No
- s& e b. k# a) x( \Bevacizumab + temsirolimus Yes
, l3 s& e1 M- \4 N& X8 J) e zBevacizumab + everolimus Yes 4 k$ ~9 c* W- m1 ^
Sorafenib + sunitinib ? 4 n4 o0 |. C5 @! u& ]
Sorafenib + temsirolimus Yes, reduced dose
6 M# N) i5 Q3 l+ d$ qSorafenib + everolimus Yes, reduced dose
) @ D6 h5 V, r5 X6 Z# Q& sSunitinib + temsirolimus† No ! b- N7 r& a1 s" u
Sunitinib + everolimus ? ; ^! G8 k6 ?4 E
Temsirolimus + everolimus ? 1 F, i/ V+ _! s& `1 }# w& J
————————————————————" j( h& I( o9 d% e5 f, B
†Led to US FDA warning.
# g( c4 Y" B' c( S1 u0 U2 k, Y?: As yet unattempted combination.: W) k1 z/ c8 w* Y. {7 ~
|